Vivace Therapeutics

Founded in 2014 and headquartered in San Mateo, US, Vivace Therapeutics focuses on oncology and has undergone strategic pivots to refine its product offerings.Vivace Therapeutics specializes in the discovery and development of small-molecule therapeutics targeting the Hippo-YAP pathway, which plays a critical role in regulating cell proliferation and apoptosis. The company's core product, VT3989, is a first-in-class inhibitor of the YAP-TEAD transcription complex, currently undergoing a Phase 1 clinical trial for advanced solid tumors, specifically malignant mesothelioma and tumors with neurofibromatosis type 2 (NF2) mutations. This innovative therapeutic aims to provide new treatment options for patients suffering from various cancers, including those that are resistant to existing therapies. Vivace also explores the potential of their YAP-TEAD inhibitors in non-oncology indications, such as fibrotic diseases, thereby expanding their market reach.Vivace Therapeutics operates through a model that engages in direct collaboration with clinical research organizations and healthcare providers, focusing particularly on the oncology sector. The company's revenue generation is primarily derived from strategic partnerships and collaborations aimed at advancing their clinical programs, particularly those associated with VT3989. These transactions enable Vivace to secure the necessary resources for ongoing clinical trials and further development of their therapeutic offerings.In February 2025, Vivace Therapeutics, Inc. Additionally, Vivace aims to target expansion in both North America and Asia, with potential new product launches and geographical outreach planned for the coming years.

1. Series D

   Feb 28, 2025

   Amount

   $18M

   Investors

   Locked

2. Series C

   Dec 11, 2020

   Amount

   $30M

   Investors

   Locked

3. Series B

   May 5, 2017

   Amount

   $8M

   Investors

   Locked

4. Series A

   Jan 1, 2015

   Amount

   $15M

   Investors

   Locked